← Leaderboards
Camelia Sima
Sloan-Kettering Inst Can Research
$250,398
Attributed
$857,607
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $480.6K · FY2012–13$500K$375K$250K$125K$0
'12
'13
Funding mix
By agency
NIH$857,607 · 2
By mechanism
R21$857,607 · 2
Top collaborators
- Prasad S. Adusumilli4 shared
- Santosh Kumar Patnaik2 shared
- Nabil Rizk2 shared
- Laura Tang2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Prasad S. Adusumilli$7,809,681
- Raymond J Muller$2,385,467
- Marjorie G. Zauderer$2,538,334
- Samuel Singer$8,089,401
- Aimee Marie Crago$2,751,471
Others in their field
Top investigators on “Databases”
- David Heimbrook · Leidos Biomedical Research, Inc.$455,970,032
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$335,843,535
- David R. Weir · University Of Michigan At Ann Arbor$325,731,040
- James Dennis Neaton · Northwestern University$268,647,311
- George R Seage · Abt Associates, Inc.$256,840,535
- Richard K. Wilson · Washington University$204,375,149
Research focus
DatabasesAdjuvant TherapyPublicationsValidationRecurrenceExcisionHigh RiskProtocols DocumentationStagingTumorTissuesResearch ProposalsOperative Surgical ProceduresInstrumentChestCharacteristicsBloodCessation Of LifeCell SurfaceBiomarkerAftercareCost EffectiveDesignCandidate Selection
Grant awards (4)
Validation of a risk model for stage I lung adenocarcinoma$190,021
R21 · FY2013 · CA
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma$186,970
R21 · FY2013 · CA
Validation of a risk model for stage I lung adenocarcinoma$241,931
R21 · FY2012 · CA
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma$238,685
R21 · FY2012 · CA